An Analysis of the tnAcity Trial

Video

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer (TNBC).

Clinical Pearls:

  • The tnAcity trial will measure the efficacy of combinations, such as gemcitabine and carboplatin, carboplatin and nab-paclitaxel (Abraxane), and gemcitabine and nab-paclitaxel
  • During this phase II trial, which has about 80 patients enrolled, patients will be randomized to receive one of the three combinations
  • Based on the results of the phase II trial, the two combinations that prove to be the most effective will be tested further
  • The trial will also investigate biomarkers that will help physicians figure out how to optimally treat patients with TNBC
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content